Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1335
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer ; volume:147 ; number:5 ; day:3 ; month:3 ; year:2021 ; pages:1421-1430 ; date:5.2021
Journal of cancer research and clinical oncology ; 147, Heft 5 (3.3.2021), 1421-1430, 5.2021
- Creator
-
Hanker, L. C.
El-Balat, A.
Drosos, Z.
Kommoss, S.
Karn, T.
Holtrich, U.
Gitas, G.
Graeser-Mayer, M.
Anglesio, M.
Huntsman, D.
Rody, A.
Gevensleben, H.
Hoellen, F.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-021-03558-x
- URN
-
urn:nbn:de:101:1-2021052722350119571633
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hanker, L. C.
- El-Balat, A.
- Drosos, Z.
- Kommoss, S.
- Karn, T.
- Holtrich, U.
- Gitas, G.
- Graeser-Mayer, M.
- Anglesio, M.
- Huntsman, D.
- Rody, A.
- Gevensleben, H.
- Hoellen, F.
- SpringerLink (Online service)
Other Objects (12)
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Immune cell landscapes are associated with high-grade serous ovarian cancer survival
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Immune cell landscapes are associated with high-grade serous ovarian cancer survival
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
High-throughput approaches for precision medicine in high-grade serous ovarian cancer